BridgeMD
New treatment option for Cleft Palate Children
Official title Effect of Infant Sign Training on Speech-language Development
ClinicalTrials.gov ID: NCT06143254
What this study is testing
- What it's testing
- Children born with a cleft lip and palate (CLP) are known to be at risk for speech-language disorders that impact academic and social emotional growth. Even at very young ages (\<3 years), speech-language disorders are already observed.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 24
You may be able to join if
- Born with cleft palate (with or without cleft lip)
- Having Dutch as mother tongue
You likely can't join if
- syndromic cleft
- more than mild hearing loss (i.e. \> 40dB hearing threshold bilaterally)
- neurosensory hearing loss
- cognitive delay
- motor delay
The study team makes the final eligibility decision.
Where it's taking place
- Ghent, East Flanders, Belgium
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 months to 24 months. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ghent, East Flanders, Belgium. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.